Treatment of amyloidoses using myelin basic protein and fragments thereof
View Patent ↗In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibrillization of peptides implicated in the amyloidoses, especially the amyloid-b eta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.
1. A method of treating a subject having an amyloid disease or disorder, wherein said subject comprises at least one fibril, comprising administering a composition comprising a peptide consisting of a myelin basic protein fragment, wherein said fragment consists of the amino acid sequence KRGX 1 X 2 X 3 X 4 X 5 X 6 HP (SEQ ID NO: 1), wherein X 1 -X 6 are amino acids selected from the group consisting of G, P, A, V, L, I, M, C, F, Y, W, H, K, R, Q, N, E, D, S and T, wherein said amyloid disease or disorder is ameliorated.
2. The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable vehicle, wherein said vehicle is targeted to said at least one fibril.
3. The method of claim 1 , wherein said administering contacts said composition with a brain tissue of said subject.
4. The method of claim 1 , wherein said myelin basic protein fragment is KRGSGKVPWLK (SEQ ID NO:4).
5. The method of claim 1 , wherein said amyloid disease or disorder is selected from the group consisting of Alzheimer's disease, cerebral amyloid angiopathy, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, laughing death syndrome, scrapie, and Lewy body dementia.
6. The method of claim 1 , wherein said at least one fibril comprises at least one fibrillizing peptide.
7. The method of claim 6 , wherein said at least one fibrillizing peptide is an Aβ peptide.
8. The method of claim 6 , wherein said myelin basic protein fragment interferes with said at least one fibrillizing peptide such that formation of a plaque is inhibited.
9. A method of treating a subject having an amyloid disease or disorder, wherein said subject comprises at least one fibril comprising administering a composition comprising a vector encoding a peptide consisting of a myelin basic protein fragment, wherein said fragment consists of the amino acid sequence KRGX 1 X 2 X 3 X 4 X 5 X 6 HP (SEQ ID NO: 1), wherein X 1 -X 6 are amino acids selected from the group consisting of G, P, A, V, L, I, M, C, F, Y, W, H, K, R, Q, N, E, D, S and T, wherein said amyloid disease or disorder is ameliorated.
10. The method of claim 9 , wherein said composition further comprises a pharmaceutically acceptable vehicle, wherein said vehicle is targeted to said at least one fibril.
11. The method of claim 10 , wherein said pharmaceutically acceptable vehicle comprises a nanoparticle vehicle.
12. The method of claim 10 , wherein said pharmaceutically acceptable vehicle comprises a vector-based delivery vehicle.
13. The method of claim 9 , wherein said administering contacts said composition with a brain tissue of said subject.
14. The method of claim 9 , wherein said myelin basic protein fragment is KRGSGKVPWLK (SEQ ID NO:4).
15. The method of claim 9 , wherein said amyloid disease or disorder is selected from the group consisting of Alzheimer's disease, cerebral amyloid angiopathy, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, laughing death syndrome, scrapie, and Lewy body dementia.
16. The method of claim 9 , wherein said fibril comprises at least one fibrillizing peptide.
17. The method of claim 9 , wherein said at least one fibrillizing peptide is an Aβ peptide.
18. The method of claim 9 , wherein said myelin basic protein fragment interferes with said at least one fibrillizing peptide such that formation of a plaque is inhibited.